Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.04 USD
Change Today -0.0008 / -2.08%
Volume 9.1M
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

cannabis science inc (CBIS) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/4/14 - $0.10
52 Week Low
08/6/15 - $0.01
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CANNABIS SCIENCE INC (CBIS)

cannabis science inc (CBIS) Related Bloomberg News

View More Bloomberg News

cannabis science inc (CBIS) Related Businessweek News

No Related Businessweek News Found

cannabis science inc (CBIS) Details

Cannabis Science, Inc. develops, produces, and commercializes phytocannabinoid-based pharmaceutical products. It develops medicines to treat autism, blood pressure, cancer, and cancer side effects, as well as other illnesses, including general health maintenance. The company is developing CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as for those intolerant of available therapies; CS-S/BCC-1 for basal and squamous cell carcinomas; and a proprietary cannabis-based therapy for neurological conditions. In addition, it provides an online video-based medical cannabis education system comprising various courses, such as medical cannabis law, medical marijuana, cooking, horticulture, and bud tending. The company has a license agreement with Apothecary Genetics Investments LLC. to produce various brand formulations for California medical cannabis market. Cannabis Science, Inc. is based in Colorado Springs, Colorado.

cannabis science inc (CBIS) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $114.8K
Co-Founder, Chief Operating Officer, General ...
Total Annual Compensation: $45.0K
Chief Financial Officer and Director
Total Annual Compensation: $22.5K
President of European Operations and Director
Total Annual Compensation: $22.5K
Chairman of Scientific Advisory Board and Cli...
Total Annual Compensation: $105.0K
Compensation as of Fiscal Year 2014.

cannabis science inc (CBIS) Key Developments

Mark Wainberg Joins Scientific Advisory Board of Cannabis Science, Inc

Cannabis Science, Inc. announced the addition of Mark Wainberg, Ph.D., Director of the McGill University AIDS Centre at the Montreal Jewish General Hospital and Professor of Medicine and of Microbiology at McGill University. r. Wainberg holds a prestigious place in the history of the HIV field. His laboratory at the McGill University AIDS Center primarily studies HIV reverse transcriptase, the molecular basis for drug resistance, and gene therapy.

Cannabis Science, Inc. Signs Research and Distribution Agreement with Cannabis Science Research Foundation

Cannabis Science, Inc. has signed a research and distribution agreement with Cannabis Science Research Foundation (CSRF). The CSRF will be responsible for the release and distribution of the CBIS products for its initial State-by-State initiatives in California. The CSRF distribution agreement is due to the committed focus CBIS has on its federal drug development program. As a result of this new agreement with CSRF the Cannabis Science Patient Access Center will be moved to the CSRF website as well. CSRF will be responsible for all of the CBIS State-by-State initiatives followed by Colorado, Washington, and subsequent States as scheduled products become available for distribution. The much-anticipated California release includes new extract products that will be the first in line and scheduled for release next week in California. This first batch of extracts will be followed by the second batch consisting of pill type capsules for oral consumption. These initial products will be available in a variety of dosage strengths, and subsequent products will be released in succession throughout the State of California.

Cannabis Science, Inc. Enters into Joint Development Agreement with IGXBio, Inc

On May 21, 2015, Cannabis Science, Inc. (the Company), entered into a Joint Development Agreement with IGXBio, Inc., a Delaware corporation (IGXB). Pursuant to the Agreement the Company and IGXB will jointly develop and conduct a clinical protocol for an anti-inflammatory utilizing cannabinoids and GenePro, a DNA based immunotherapy with a FDA IND number. Each company will retain ownership of their respective intellectual property and equally own any new products or drugs derived from the Agreement. The term of the Agreement is initially for 4 years with an automatic renewal provision. The Company will issue IGXB 5 million shares of restricted common stock pursuant to the Agreement.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBIS:US $0.04 USD -0.0008

CBIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
GW Pharmaceuticals PLC 596.00 GBp +13.50
Medical Marijuana Inc $0.04 USD -0.0015
PharmaCyte Biotech Inc $0.10 USD -0.0015
View Industry Companies

Industry Analysis


Industry Average

Valuation CBIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CANNABIS SCIENCE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at